Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Today's Technical View: Zoetis, Covidien, Teva Pharma, and Valeant Pharma



  Today's Technical View: Zoetis, Covidien, Teva Pharma, and Valeant Pharma

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

LONDON, July 18, 2013

LONDON, July 18, 2013 /PRNewswire/ --

On Wednesday, July 17, 2013, shares in healthcare companies ended on a mixed
note even as the broader market edged higher. The major movers in the sector
included Zoetis Inc. (NYSE: ZTS), Covidien Plc (NYSE: COV), Teva
Pharmaceuticals Industries Ltd. (ADR) (NYSE: TEVA), and Valeant
Pharmaceuticals International Inc. (NYSE: VRX). All these companies are
tracked by AAAResearchReports.com. Free in-depth technical analysis on ZTS,
COV, TEVA, and VRX are currently available upon sign up at:

http://www.aaaresearchreports.com/register/  

Shares in Zoetis Inc. edged lower on Wednesday even as the broader market
edged higher. The company's shares ended the day 0.55% lower at $30.99 after
oscillating between $30.85 and $31.23. A total of 3.55 million shares were
traded which is below the daily average volume of 13.03 million. The company's
shares have gained 0.10% in the last one month as compared to a gain of 2.55%
in the S&P 500. In the last three months, the stock has fallen by 5.78% as
opposed to a gain of 8.31% in the S&P 500. Sign up for free technical analysis
on ZTS at:

http://www.AAAResearchReports.com/ZTS071813.pdf

Covidien Plc's stock edged higher on Wednesday, ending the day at $60.46, up
0.65% from its previous closing price. The company's shares oscillated between
$60.17 and $60.75. A total of 2.57 million shares were traded which is below
the daily average volume of 2.77 million. The stock is trading above its
50-day and 200-day moving averages. Download the free report on COV by
registering at:

http://www.AAAResearchReports.com/COV071813.pdf

Shares in Teva Pharmaceuticals Industries Ltd edged higher on Wednesday,
tracking gains in the broader market. The company's shares oscillated between
$39.35 and $39.77 before closing the day 0.84% higher at $39.74. A total of
3.26 million shares were traded which is below the daily average volume of
3.31 million. The company's shares have gained 1.07% in the last one month and
3.52% in the last three months. The free report on TEVA can be downloaded by
signing up now at:

http://www.AAAResearchReports.com/TEVA071813.pdf

Valeant Pharmaceuticals International Inc.'s stock slipped on Wednesday,
closing at $91.45, down 0.09% from the previous trading session. The company's
shares fluctuated between $90.69 and $92.68. A total of 1.28 million shares
were traded which is below the daily average volume of 1.85 million. The
company's shares have gained 7.82% in the last one month and 25.51% in the
last three months, thus outperforming the S&P 500 during the respective
periods. Moreover, the stock is currently trading near its 52-week high of
$96.25. A free report on VRX can be accessed by registering at:

http://www.AAAResearchReports.com/VRX071813.pdf

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE AAA Research Reports

Contact: AAAresearchreports.com Phone #: +1(646)396-9126
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement